FURTHER CLINICAL TRIALS WITH PORFIROMYCIN (NSC-56410) (LARGE INTERMITTENT DOSES)IZBICKI R; MUHYI AL SARRAF; REED ML et al.sdCANCER CHEMOTHERAPY REP., 1; U.S.A.; DA. 197; VOL. 56; NO 5; PP. 615-624; BIBL. 3REF.Serial Issue

Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cellsSU-SHU PAN; JOHNSON, R; GONZALEZ, H et al.Cancer research (Baltimore). 1989, Vol 49, Num 18, pp 5048-5053, issn 0008-5472, 6 p.Article

PHASE I STUDIES OF PORFIROMYCIN (NSC-56410) IN SOLID TUMORS.GRAGE TB; WEISS AJ; WILSON W et al.1975; J. SURG. ONCOL.; U.S.A.; DA. 1975; VOL. 7; NO 5; PP. 415-420; BIBL. 10 REF.Article

MITOMYCINS: CHEMISTRY, MICROBIOLOGY & PHARMACOLOGYABOU ZEID ALI ABOU ZEID; ABD EL SADEK ABOU EL ATTA YOUSEF.1975; J. SCI. INDUSTR. RES.; INDIA; DA. 1975; VOL. 34; NO 12; PP. 665-678; BIBL. 3 P. 1/2Article

Preclinical studies of porfiromycin as an adjunct to radiotherapyROCKWELL, S; KEYES, S. R; SARTORELLI, A. C et al.Radiation research. 1988, Vol 116, Num 1, pp 100-113, issn 0033-7587Article

Production of mitomycin C and porfiromycin by Streptomyces speciesMANDWAL, A. K; SUBRAMANIAN, P. M; BHATIA, M. C et al.Journal of natural products (Print). 1985, Vol 48, Num 2, issn 0163-3864, 334Article

Isolation and identification of urinary metabolites of porfiromycin in dogs and humansWENSHENG LANG; MAO, J; DOYLE, T. W et al.Drug metabolism and disposition. 2000, Vol 28, Num 8, pp 899-904, issn 0090-9556Article

DEVELOPMENT OF NEW MITOMYCIN C AND PORFIROMYCIN ANALOGUESIYENGAR BS; LIN HJ; CHENG L et al.1981; J. MED. CHEM.; ISSN 0022-2623; USA; DA. 1981; VOL. 24; NO 8; PP. 975-981; BIBL. 16 REF.Article

MITOMYCIN C AND PORFIROMYCIN ANALOGUES WITH SUBSTITUTED ETHYLAMINES AT POSITION 7IYENGAR BS; SAMI SM; REMERS WA et al.1983; J. MED. CHEM.; ISSN 0022-2623; USA; DA. 1983; VOL. 26; NO 1; PP. 16-20; BIBL. 7 REF.Article

SYNTHETIC STUDIES TOWARD MITOMYCINS. II. TOTAL SYNTHESIS OF DL-PORFIROMYCIN.NAKATSUBO F; FUKUYAMA T; COCUZZA AJ et al.1977; J. AMER. CHEM. SOC.; U.S.A.; DA. 1977; VOL. 99; NO 24; PP. 8115-8116; BIBL. 20 REF.Article

Generation of reactive oxygen radicals through bioactivation of mitomycin antibioticsPRITSOS, C. A; SARTORELLI, A. C.Cancer research (Baltimore). 1986, Vol 46, Num 7, pp 3528-3532, issn 0008-5472Article

Isolation and identification of metabolites of porfiromycin formed in the presence of a rat liver preparationWENSHENG LANG; MAO, J; QIN WANG et al.Journal of pharmaceutical sciences. 2000, Vol 89, Num 2, pp 191-198, issn 0022-3549Article

BIOSYNTHESIS OF THE MITOMYCIN ANTIBIOTICS FROM 3-AMINO-5-HYDROXYBENZOIC ACIDANDERSON MG; KIBBY JJ; RICKARDS RW et al.1980; J. CHEM. SOC., CHEM. COMMUN.; ISSN 0022-4936; GBR; DA. 1980; NO 24; PP. 1277-1278; BIBL. 14 REF.Article

DNA CROSSLINKING, SISTER-CHROMATID EXCHANGE AND SPECIFIC-LOCUS MUTATIONSCARRANO AV; THOMPSON LH; STETKA DG et al.1979; MUTATION RES.; NLD; DA. 1979; VOL. 63; NO 1; PP. 175-188; BIBL. 48 REF.Article

PHASE II STUDY OF PORFIROMYCIN VS MITOMYCIN-C UTILIZING ACUTE INTERMITTENT SCHEDULES.BAKER LH; IZBICKI RM; VAITKEVICIUS VK et al.1976; MED. PEDIATR. ONCOL.; U.S.A.; DA. 1976; VOL. 2; NO 2; PP. 207-213; BIBL. 15 REF.Article

FACTORS THAT AFFECT RESPONSE TO CHEMOTHERAPY AND SURVIVAL OF PATIENTS WITH ADVANCED HEAD AND NECK CANCERAMER MH; MUHYL AL SARRAF; VAITKEVICIUS VK et al.1979; CANCER; USA; DA. 1979; VOL. 43; NO 6; PP. 2202-2206; BIBL. 15 REF.Article

PORFIROMYCIN IN THE MANAGEMENT OF EPIDERMOID AND TRANSITIONAL CELL CANCER: A PHASE II STUDY.PANETTIERE FJ; TAILEY RW; TORRES J et al.1976; CANCER TREATM. REP.; U.S.A.; DA. 1976; VOL. 60; NO 7; PP. 907-911; BIBL. 14 REF.Article

Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cellsKEYES, S. R; ROCKWELL, S; SARTORELLI, A. C et al.Cancer research (Baltimore). 1987, Vol 47, Num 21, pp 5654-5657, issn 0008-5472Article

Local cutaneous injury produced by mitomycin C and porfiromycinROCKWELL, S; KELLEY, M.The Cancer journal (Print). 1993, Vol 6, Num 5, pp 274-276, issn 0765-7846Article

Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitroKEYES, S. R; ROCKWELL, S; SARTORELLI, A. C et al.Cancer research (Baltimore). 1985, Vol 45, Num 8, pp 3642-3645, issn 0008-5472Article

Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urineGAO, X; AU, J. L.-S; BADALAMENT, R. A et al.Clinical cancer research. 1998, Vol 4, Num 1, pp 139-143, issn 1078-0432Article

Overexpression of the human HAP1 protein sensitizes cells to the lethal effect of bioreductive drugsPRIETO-ALAMO, M. J; LAVAL, F.Carcinogenesis (New York. Print). 1999, Vol 20, Num 3, pp 415-419, issn 0143-3334Article

Effect of pH on DNA alkylation by enzyme-activated mitomycin C and porfiromycinFANG YU; SU-SHU PAN.Molecular pharmacology. 1993, Vol 43, Num 6, pp 863-869, issn 0026-895XArticle

Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cellsMARSHALL, R. S; RAUTH, A. M.Cancer research (Baltimore). 1988, Vol 48, Num 20, pp 5655-5659, issn 0008-5472Article

THE TOTAL SYNTHESIS OF MITOMYCINSKISHI Y.1979; J. NAT. PROD.; USA; DA. 1979; VOL. 42; NO 6; PP. 549-568; BIBL. 13 REF.Article